Press Releases

The latest press releases from bridge therapeutics

02/21/18 Pharmaceutical Startup, Bridge Therapeutics, Names David H. Bergstrom, Ph.D. as New Chief Operating Officer

The innovative late development-stage pharmaceutical startup, Bridge Therapeutics, has named David H. Bergstrom, Ph.D. as its new Chief Operating Officer effective immediately.

February 21, 2018

Dr. Bergstrom has more than 30 years of new product development and commercialization experience in the pharmaceutical industry. He has overseen and been intimately involved in moving new products from the research phase to eventual successful commercial production. He has also launched products across numerous therapeutic areas and dosage form delivery technologies.

Dr. Bergstrom earned his Ph.D., M.S. and B.S. degrees in Pharmaceutics, Pharmaceutical Chemistry and Pharmacy from the University of Utah, The University of Michigan and Ferris State University, respectively.

Read More

05/19/17 Bridge Therapeutics to Present at BioTrinity 2017 Conference in London

CEO Dr. Greg Sullivan to introduce Bridge and its investigational drug BT-205 to investors and industry executives

May 10, 2017

(PRNewswire) — Bridge Therapeutics, Inc., an innovative development-stage specialty pharmaceutical company, announced that its CEO and Chief Scientific Officer Greg Sullivan, MD, presented at BioTrinity 2017 in London on Thursday, May 11. BioTrinity is Europe’s leading biopartnering and investment conference and the largest of its type in the UK. The conference, in its 11th year, draws attendees from approximately 30 countries and includes more than 1,000 delegates, dozens of exhibitors, and industry leaders from investment firms and global pharma.

Dr. Sullivan’s presentation to key investors and senior industry executives focused on the story of Bridge Therapeutics and its investigational drug compound BT-205, a unique combination of two synergistic chronic pain drugs—the partial-agonist opioid buprenorphine and the NSAID meloxicam—delivered in a state-of-the-art sublingual formulation.

Read more


For more information about Bridge Therapeutics please contact us today using the form below.